A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Res
Hlavní autoři: Sweet, Kendra, Hazlehurst, Lori, Sahakian, Eva, Powers, John, Nodzon, Lisa, Kayali, Fadi, Hyland, Kelly, Nelson, Ashley, Pinilla-Ibarz, Javier
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787269/
https://ncbi.nlm.nih.gov/pubmed/30340199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.10.002
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky